Latest stories on TEVA
Teva Earnings Call Highlights Innovative Growth Shift
TipRanks56 · neutralearnings
Teva outlines higher 2026 revenue midpoint by $75M while targeting AUSTEDO $2.45B-$2.6B and AJOVY $850M-$870M
Seeking Alpha67 · bullishearnings
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Teva’s Pivot to Growth Accelerates: Innovative Brands Surge 43% and 2026 Outlook Raised Despite Generics Decline
July 29, 2026
MarketChameleon73 · bullishearnings
Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss
InvestorsHub58 · neutralearnings
Why is Teva Pharma stock surging today?
Investing.com Markets50 · neutralgeneral
Teva posts Q2 revenue beat; to seek direct listing in U.S.
Seeking Alpha63 · neutralgeneral
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook | TEVA Stock News
StockTitan68 · bullishearnings
Teva’s Key Brands Drive Portfolio Transformation as Innovation Pipeline Expands
July 29, 2026
MarketChameleon67 · bullishproduct/pr
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook | TEVA Stock News
StockTitan67 · bullishearnings
Teva Pharmaceutical gives mixed Q2 results, raises outlook
Seeking Alpha56 · neutralearnings
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF) files 8-K
SEC 8-K50 · neutralgeneral
Teva Stock Is Rebounding. Its Drug Pipeline Holds the Key to Growth.
Barron's63 · neutralproduct/pr
Teva's Q2 earnings on deck: What to expect
Seeking Alpha38 · neutralearnings
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.
Yahoo Top67 · bullishproduct/pr
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.
The Motley Fool67 · bullishproduct/pr
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.
Yahoo Finance67 · bullishanalyst
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.
The Motley Fool67 · bullishanalyst
Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat
Barron's58 · neutralanalyst
Piper Sandler reiterates Teva stock rating on vitiligo drug potential
Investing.com Analyst Ratings56 · neutralanalyst
Teva on track to snap seven straight sessions of losses
Seeking Alpha53 · neutralgeneral
Teva, Polpharma ink licensing pact for biosimilar targeting Roche’s Ocrevus
Seeking Alpha63 · neutralm&a
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Business Insider63 · neutralproduct/pr